Piper Sandler initiated coverage of Zura Bio with an Overweight rating and $26 price target. The analyst sees potential for the company to become a key immunology player. Zura’s three assets, tibulizumab, ZB-168 and torudokimab, each have pipeline-in-a-product opportunity, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA: